Immunotoxins
Protocol to be started:
Principal investigator:
Steinar Aamdal MD,PhD, Department of Oncology, DNR
Co-investigators:
Olav Engebraaten MD,Phd, Department of Oncology, DNR
Paal Brunsvig MD,PhD, Department of Oncology, DNR
Øystein Fodstad MD,PhD, Department of Tumorbiology, DNR
A Phase I study : Can therapeutic concentrations of the anti EGP2 immunotoxin conjugate MOC31-PE be achieved in patients with antigen positive carcinomas?
Disease advanced mammary,lung,colorectal or prostate cancer.
Principal investigator:
Steinar Aamdal MD,PhD, Department of Oncology, DNR
Co-investigators:
Olav Engebraaten MD,Phd, Department of Oncology, DNR
Paal Brunsvig MD,PhD, Department of Oncology, DNR
Øystein Fodstad MD,PhD, Department of Tumorbiology, DNR
A Phase I study : Can therapeutic concentrations of the anti EGP2 immunotoxin conjugate MOC31-PE be achieved in patients with antigen positive carcinomas?
Disease advanced mammary,lung,colorectal or prostate cancer.